166 related articles for article (PubMed ID: 28819760)
41. Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors.
Hoffman J; Chakrabarti J; Plotka A; Milillo Naraine A; Kanamori D; Moroose R; Nguyen L; Wang D; Wainberg ZA
Anticancer Drugs; 2019 Jun; 30(5):523-532. PubMed ID: 30875341
[TBL] [Abstract][Full Text] [Related]
42. Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.
Siddiqi T; Frankel P; Beumer JH; Kiesel BF; Christner S; Ruel C; Song JY; Chen R; Kelly KR; Ailawadhi S; Kaesberg P; Popplewell L; Puverel S; Piekarz R; Forman SJ; Newman EM
Leuk Lymphoma; 2020 Feb; 61(2):309-317. PubMed ID: 31617432
[TBL] [Abstract][Full Text] [Related]
43. Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.
Cervantes A; Elez E; Roda D; Ecsedy J; Macarulla T; Venkatakrishnan K; Roselló S; Andreu J; Jung J; Sanchis-Garcia JM; Piera A; Blasco I; Maños L; Pérez-Fidalgo JA; Fingert H; Baselga J; Tabernero J
Clin Cancer Res; 2012 Sep; 18(17):4764-74. PubMed ID: 22753585
[TBL] [Abstract][Full Text] [Related]
44. Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma.
Zullo KM; Guo Y; Cooke L; Jirau-Serrano X; Mangone M; Scotto L; Amengual JE; Mao Y; Nandakumar R; Cremers S; Duong J; Mahadevan D; O'Connor OA
Clin Cancer Res; 2015 Sep; 21(18):4097-109. PubMed ID: 25878331
[TBL] [Abstract][Full Text] [Related]
45. Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas.
Song A; Andrews DW; Werner-Wasik M; Kim L; Glass J; Bar-Ad V; Evans JJ; Farrell CJ; Judy KD; Daskalakis C; Zhan T; Shi W
Radiother Oncol; 2019 Mar; 132():135-141. PubMed ID: 30825962
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer.
Tan W; Giri N; Quinn S; Wilner K; Parivar K
Invest New Drugs; 2020 Jun; 38(3):874-884. PubMed ID: 31858327
[TBL] [Abstract][Full Text] [Related]
47. Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations.
Dees EC; Cohen RB; von Mehren M; Stinchcombe TE; Liu H; Venkatakrishnan K; Manfredi M; Fingert H; Burris HA; Infante JR
Clin Cancer Res; 2012 Sep; 18(17):4775-84. PubMed ID: 22767670
[TBL] [Abstract][Full Text] [Related]
48. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.
Lin J; Patel SA; Sama AR; Hoffman-Censits JH; Kennedy B; Kilpatrick D; Ye Z; Yang H; Mu Z; Leiby B; Lewis N; Cristofanilli M; Kelly WK
Oncologist; 2016 Nov; 21(11):1296-1297e. PubMed ID: 28178640
[TBL] [Abstract][Full Text] [Related]
49. An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.
Durlacher CT; Li ZL; Chen XW; He ZX; Zhou SF
Clin Exp Pharmacol Physiol; 2016 Jun; 43(6):585-601. PubMed ID: 26999067
[TBL] [Abstract][Full Text] [Related]
50. Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.
Iankov ID; Kurokawa CB; D'Assoro AB; Ingle JN; Domingo-Musibay E; Allen C; Crosby CM; Nair AA; Liu MC; Aderca I; Federspiel MJ; Galanis E
Cancer Gene Ther; 2015 Sep; 22(9):438-44. PubMed ID: 26272026
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Matulonis UA; Sharma S; Ghamande S; Gordon MS; Del Prete SA; Ray-Coquard I; Kutarska E; Liu H; Fingert H; Zhou X; Danaee H; Schilder RJ
Gynecol Oncol; 2012 Oct; 127(1):63-9. PubMed ID: 22772063
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies.
Gong X; Ji T; Liu X; Chen X; Yeleswaram S
Pharmacol Res Perspect; 2022 Feb; 10(1):e00906. PubMed ID: 34951522
[TBL] [Abstract][Full Text] [Related]
53. Alisertib (MLN8237), a selective Aurora-A kinase inhibitor, induces apoptosis in human tongue squamous cell carcinoma cell both in vitro and in vivo.
Qi L; Zhang Y
Tumour Biol; 2015 Mar; 36(3):1797-802. PubMed ID: 25366143
[TBL] [Abstract][Full Text] [Related]
54. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
55. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
56. Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study.
Shen Z; Gillen M; Tieu K; Nguyen M; Harmon E; Wilson DM; Kerr B; Lee CA
Drug Des Devel Ther; 2016; 10():3509-3517. PubMed ID: 27826183
[TBL] [Abstract][Full Text] [Related]
57. MLN8237 ( alisertib ) and its role in peripheral T-cell lymphoma.
Alrifai D; Pettengell R
Expert Opin Investig Drugs; 2014 Dec; 23(12):1731-6. PubMed ID: 25323772
[TBL] [Abstract][Full Text] [Related]
58. Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.
Bendell JC; Patel MR; Yoshida K; Seraj J; Weaver R; Lemech C; Todaro TG; Pant S; Arkenau HT
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1275-83. PubMed ID: 27151157
[TBL] [Abstract][Full Text] [Related]
59. Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors.
Patel C; Goel S; Patel MR; Rangachari L; Wilbur JD; Shou Y; Venkatakrishnan K; Lockhart AC
Clin Pharmacol Drug Dev; 2020 Oct; 9(7):876-888. PubMed ID: 32488989
[TBL] [Abstract][Full Text] [Related]
60. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]